-
公开(公告)号:US07576085B2
公开(公告)日:2009-08-18
申请号:US11272392
申请日:2005-11-10
申请人: Timothy J. Guzi , Kamil Paruch , Michael P. Dwyer , Lianyun Zhao , Patrick J. Curran , David B. Belanger , Blake Hamann , Panduranga A. Reddy , M. Arshad Siddiqui
发明人: Timothy J. Guzi , Kamil Paruch , Michael P. Dwyer , Lianyun Zhao , Patrick J. Curran , David B. Belanger , Blake Hamann , Panduranga A. Reddy , M. Arshad Siddiqui
IPC分类号: A01N43/58 , A01N43/60 , A61K31/50 , A61K31/495 , C07D403/00 , C07D471/00 , C07D487/00 , C07D491/00 , C07D495/00 , C07D497/00
CPC分类号: C07D487/04
摘要: In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. An illustrative compound of the invention is shown below:
摘要翻译: 在其许多实施方案中,本发明提供了一类新颖的咪唑并[1,2-a]吡嗪化合物作为细胞周期蛋白依赖性激酶的抑制剂,制备此类化合物的方法,含有一种或多种此类化合物的药物组合物,制备药物制剂的方法 包括一种或多种这样的化合物,以及使用这些化合物或药物组合物治疗,预防,抑制或改善与CDK相关的一种或多种疾病的方法。 本发明的说明性化合物如下所示:
-
公开(公告)号:US07511040B2
公开(公告)日:2009-03-31
申请号:US11936380
申请日:2007-11-07
申请人: David B. Belanger , M. Arshad Siddiqui , Timothy J. Guzi , Patrick J. Curran , Praveen K. Tadikonda , Blake Hamann , Panduranga Adulla P. Reddy , Lianyun Zhao
发明人: David B. Belanger , M. Arshad Siddiqui , Timothy J. Guzi , Patrick J. Curran , Praveen K. Tadikonda , Blake Hamann , Panduranga Adulla P. Reddy , Lianyun Zhao
IPC分类号: C07D471/02
CPC分类号: C07D487/04
摘要: In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or Aurora kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or Aurora kinases using such compounds or pharmaceutical compositions. An illustrative compound of the invention is shown below:
摘要翻译: 在其许多实施方案中,本发明提供了一类新颖的咪唑并吡嗪化合物作为蛋白质和/或极光激酶的抑制剂,制备这些化合物的方法,包含一种或多种这样的化合物的药物组合物,制备药物制剂的方法,包括一种或多种这样的化合物 化合物,以及使用这些化合物或药物组合物治疗,预防,抑制或改善与蛋白质或极光激酶相关的一种或多种疾病的方法。 本发明的说明性化合物如下所示:
-
公开(公告)号:US20080139571A1
公开(公告)日:2008-06-12
申请号:US11936380
申请日:2007-11-07
申请人: David B. Belanger , M. Arshad Siddiqui , Timothy J. Guzi , Patrick J. Curran , Praveen K. Tadikonda , Blake Hamann , Panduranga Adulla P. Reddy , Lianyun Zhao
发明人: David B. Belanger , M. Arshad Siddiqui , Timothy J. Guzi , Patrick J. Curran , Praveen K. Tadikonda , Blake Hamann , Panduranga Adulla P. Reddy , Lianyun Zhao
IPC分类号: A61K31/519 , C07D487/04 , A61P35/00
CPC分类号: C07D487/04
摘要: In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or Aurora kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or Aurora kinases using such compounds or pharmaceutical compositions.
摘要翻译: 在其许多实施方案中,本发明提供了一类新颖的咪唑并吡嗪化合物作为蛋白质和/或极光激酶的抑制剂,制备这些化合物的方法,包含一种或多种这样的化合物的药物组合物,制备药物制剂的方法,包括一种或多种这样的化合物 化合物,以及使用这些化合物或药物组合物治疗,预防,抑制或改善与蛋白质或极光激酶相关的一种或多种疾病的方法。
-
4.
公开(公告)号:US20100130465A1
公开(公告)日:2010-05-27
申请号:US12447710
申请日:2007-10-29
申请人: Gerald W. Shipps, JR. , Cliff C. Cheng , Xiaohua Huang , Thierry O. Fischmann , Jose S. Duca , Matthew Richards , Hongbo Zeng , Binyuan Sun , Panduranga A. Reddy , Lianyun Zhao , Shuyi Tang , Tzu T. Wong , Praveen K. Tadikonda , Luis E. Torres , M. Arshad Siddiqui , Michael P. Dwyer , Kartik M. Keertikar , Timothy J. Guzi
发明人: Gerald W. Shipps, JR. , Cliff C. Cheng , Xiaohua Huang , Thierry O. Fischmann , Jose S. Duca , Matthew Richards , Hongbo Zeng , Binyuan Sun , Panduranga A. Reddy , Lianyun Zhao , Shuyi Tang , Tzu T. Wong , Praveen K. Tadikonda , Luis E. Torres , M. Arshad Siddiqui , Michael P. Dwyer , Kartik M. Keertikar , Timothy J. Guzi
IPC分类号: A61K31/438 , C07D417/14 , A61K31/497 , C07D471/10 , C07D413/14 , A61K31/5377 , A61K31/551
CPC分类号: C07D277/56 , A61K31/435 , A61K31/439 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/551 , A61K45/06 , C07D417/04 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D513/04 , A61K2300/00
摘要: The present invention relates to novel Anilinopiperazine Derivatives of formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.
摘要翻译: 本发明涉及式(I)的新型苯胺基哌嗪衍生物,包含苯胺基哌嗪衍生物的组合物,以及使用苯胺基哌嗪衍生物治疗或预防增殖性病症,抗增殖病症,炎症,关节炎,中枢神经系统疾病 ,心血管疾病,脱发,神经元疾病,缺血性损伤,病毒性疾病,真菌感染或与蛋白激酶活性相关的病症。
-
公开(公告)号:US08278337B2
公开(公告)日:2012-10-02
申请号:US12519731
申请日:2007-12-17
申请人: David B. Belanger , M. Arshad Siddiqui , Patrick J. Curran , Blake Hamann , Lianyun Zhao , Panduranga Adulla P. Reddy , Praveen K. Tadikonda , Gerald W. Shipps, Jr. , Umar Faruk Mansoor
发明人: David B. Belanger , M. Arshad Siddiqui , Patrick J. Curran , Blake Hamann , Lianyun Zhao , Panduranga Adulla P. Reddy , Praveen K. Tadikonda , Gerald W. Shipps, Jr. , Umar Faruk Mansoor
IPC分类号: A61K31/44
CPC分类号: C07D417/12 , C07D213/81 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04
摘要: Disclosed are compounds of the formula (I) wherein X is N or CH, and Y is N or CR5. Also disclosed are methods of treating JNK and ERK mediated diseases using the compounds of formula 1.0.
摘要翻译: 公开了式(I)的化合物,其中X是N或CH,Y是N或CR 5。 还公开了使用式1.0化合物治疗JNK和ERK介导的疾病的方法。
-
公开(公告)号:US20100179141A1
公开(公告)日:2010-07-15
申请号:US12519731
申请日:2007-12-17
申请人: David B. Belanger , M. Arshad Siddiqui , Patrick J. Curran , Blake Hamann , Lianyun Zhao , Panduranga Adulla P. Reddy , Praveen K. Tadikonda , Gerald W. Shipps, JR. , Umar Faruk Mansoor
发明人: David B. Belanger , M. Arshad Siddiqui , Patrick J. Curran , Blake Hamann , Lianyun Zhao , Panduranga Adulla P. Reddy , Praveen K. Tadikonda , Gerald W. Shipps, JR. , Umar Faruk Mansoor
IPC分类号: A61K31/5377 , C07D417/12 , A61K31/4439 , A61K31/4545 , C07D417/14 , C07D401/12 , C07D413/14 , C07D405/12 , A61K31/444 , A61K31/502 , A61K31/497 , C07D213/81 , A61K31/44 , C07D401/14 , A61K31/506 , C07D513/04 , A61K31/517 , C07D471/04 , A61K31/496 , A61P19/02 , A61P29/00 , A61P11/06 , A61P25/28 , A61P1/00 , A61P3/10 , A61P17/06
CPC分类号: C07D417/12 , C07D213/81 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04
摘要: Disclosed are compounds of the formula (I) wherein X is N or CH, and Y is N or CR5. Also disclosed are methods of treating JNK and ERK mediated diseases using the compounds of formula 1.0.
摘要翻译: 公开了式(I)的化合物,其中X是N或CH,Y是N或CR 5。 还公开了使用式1.0化合物治疗JNK和ERK介导的疾病的方法。
-
公开(公告)号:US07557104B2
公开(公告)日:2009-07-07
申请号:US11758243
申请日:2007-06-05
申请人: Lianyun Zhao , Panduranga Adulla P. Reddy , Neng-Yang Shih , Kamil Paruch , Timothy J. Guzi , M. Arshad Siddiqui
发明人: Lianyun Zhao , Panduranga Adulla P. Reddy , Neng-Yang Shih , Kamil Paruch , Timothy J. Guzi , M. Arshad Siddiqui
IPC分类号: A61K31/497
CPC分类号: C07D487/04
摘要: In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.
摘要翻译: 在其许多实施方案中,本发明提供了一类新颖的咪唑并吡嗪化合物作为蛋白质和/或检查点激酶的抑制剂,制备此类化合物的方法,包含一种或多种此类化合物的药物组合物,制备药物制剂的方法,包括一种或多种 化合物,以及使用这些化合物或药物组合物治疗,预防,抑制或改善与蛋白质或检查点激酶相关的一种或多种疾病的方法。
-
8.
公开(公告)号:US08318735B2
公开(公告)日:2012-11-27
申请号:US12447710
申请日:2007-10-29
申请人: Gerald W. Shipps, Jr. , Cliff C. Cheng , Xiaohua Huang , Thierry O. Fischmann , Jose S. Duca , Matthew Richards , Hongbo Zeng , Binyuan Sun , Panduranga Adulla Reddy , Lianyun Zhao , Shuyi Tang , Tzu T. Wong , Praveen K. Tadikonda , Luis E. Torres , M. Arshad Siddiqui , Michael P. Dwyer , Kartik M. Keertikar , Timothy J. Guzi
发明人: Gerald W. Shipps, Jr. , Cliff C. Cheng , Xiaohua Huang , Thierry O. Fischmann , Jose S. Duca , Matthew Richards , Hongbo Zeng , Binyuan Sun , Panduranga Adulla Reddy , Lianyun Zhao , Shuyi Tang , Tzu T. Wong , Praveen K. Tadikonda , Luis E. Torres , M. Arshad Siddiqui , Michael P. Dwyer , Kartik M. Keertikar , Timothy J. Guzi
IPC分类号: A61K31/5355 , A61K31/496 , C07D401/14 , C07D403/14 , C07D413/14
CPC分类号: C07D277/56 , A61K31/435 , A61K31/439 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/551 , A61K45/06 , C07D417/04 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D513/04 , A61K2300/00
摘要: The present invention relates to novel Anilinopiperazine Derivatives of formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.
摘要翻译: 本发明涉及式(I)的新型苯胺基哌嗪衍生物,包含苯胺基哌嗪衍生物的组合物,以及使用苯胺基哌嗪衍生物治疗或预防增殖性病症,抗增殖病症,炎症,关节炎,中枢神经系统疾病 ,心血管疾病,脱发,神经元疾病,缺血性损伤,病毒性疾病,真菌感染或与蛋白激酶活性相关的病症。
-
公开(公告)号:US09227971B2
公开(公告)日:2016-01-05
申请号:US13520274
申请日:2011-01-18
申请人: M. Arshad Siddiqui , Yang Nan , Mehul F. Patel , Panduranga Adulla P. Reddy , Umar Faruk Mansoor , Zhaoyang Meng , Lalanthi Dilrukshi Vitharana , Lianyun Zhao , Amit K. Mandal , Duan Liu , Shuyi Tang , Andrew McRiner , David B. Belanger , Patrick J. Curran , Chaoyang Dai , Angie R. Angeles , Liping Yang , Matthew Hersh Daniels
发明人: M. Arshad Siddiqui , Yang Nan , Mehul F. Patel , Panduranga Adulla P. Reddy , Umar Faruk Mansoor , Zhaoyang Meng , Lalanthi Dilrukshi Vitharana , Lianyun Zhao , Amit K. Mandal , Duan Liu , Shuyi Tang , Andrew McRiner , David B. Belanger , Patrick J. Curran , Chaoyang Dai , Angie R. Angeles , Liping Yang , Matthew Hersh Daniels
IPC分类号: C07D487/04 , A61K31/519 , C07D471/08 , C07D498/08 , C07D491/147 , C07D487/08 , C07D513/08 , C07D519/00 , A61P35/00
CPC分类号: C07D471/08 , C07D487/04 , C07D487/08 , C07D491/147 , C07D498/08 , C07D513/08 , C07D519/00
摘要: The present invention provides Pyrazolopyrimidine Compounds of Formula (I): wherein L, T, Z, U, V, W, R3, R6, R7, R8, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.
摘要翻译: 本发明提供式(I)的吡唑并嘧啶化合物:其中L,T,Z,U,V,W,R 3,R 6,R 7,R 8和m如本文所定义,以及这些吡唑并嘧啶化合物的药学上可接受的盐。 吡唑并嘧啶化合物可用于治疗其中mTOR失调的癌症和其它疾病或病症。
-
公开(公告)号:US20120322791A1
公开(公告)日:2012-12-20
申请号:US13520274
申请日:2011-01-18
申请人: M. Arshad Siddiqui , Yang Nan , Mehul F. Patel , Panduranga Adulla P. Reddy , Umar Faruk Mansoor , Zhaoyang Meng , Lalanthi Dilrukshi Vitharana , Lianyun Zhao , Amit K. Mandal , Duan Liu , Shuyi Tang , Andrew McRiner , David B. Belanger , Patrick J. Curran , Chaoyang Dai , Angie R. Angeles , Liping Yang , Matthew Hersh Daniels
发明人: M. Arshad Siddiqui , Yang Nan , Mehul F. Patel , Panduranga Adulla P. Reddy , Umar Faruk Mansoor , Zhaoyang Meng , Lalanthi Dilrukshi Vitharana , Lianyun Zhao , Amit K. Mandal , Duan Liu , Shuyi Tang , Andrew McRiner , David B. Belanger , Patrick J. Curran , Chaoyang Dai , Angie R. Angeles , Liping Yang , Matthew Hersh Daniels
IPC分类号: A61K31/519 , A61K31/5377 , C07D487/08 , A61K31/55 , A61P35/00 , C07D498/08 , A61K31/5386 , C07D513/08 , A61K31/547 , C07D491/147 , C07D487/04 , C07D471/08
CPC分类号: C07D471/08 , C07D487/04 , C07D487/08 , C07D491/147 , C07D498/08 , C07D513/08 , C07D519/00
摘要: The present invention provides Pyrazolopyrimidine Compounds of Formula (I): wherein L, T, Z, U, V, W, R3, R6, R7, R8, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.
摘要翻译: 本发明提供式(I)的吡唑并嘧啶化合物:其中L,T,Z,U,V,W,R 3,R 6,R 7,R 8和m如本文所定义,以及这些吡唑并嘧啶化合物的药学上可接受的盐。 吡唑并嘧啶化合物可用于治疗其中mTOR失调的癌症和其它疾病或病症。
-
-
-
-
-
-
-
-
-